Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established.
Gacci, M., Greco, I., Artibani, W., Bassi, P., Bertoni, F., Bracarda, S., et al. (2020). The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. MINERVA UROLOGICA E NEFROLOGICA [10.23736/S0393-2249.20.03925-9].
The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study
Artibani, Walter;Fusco, Ferdinando;Simonato, Alchiede;
2020-01-01
Abstract
Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
The_waiting_time_for_prostate_cancer_treatment_in_Italy_analysis.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
1.24 MB
Formato
Adobe PDF
|
1.24 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
